The effect of exposure to electro-capacitive cancer treatment on JNK2α2 expression and the number of glioblastoma cells

This study explores the effects of ECCT on glioblastoma (GBM), an extremely aggressive form of brain cancer. ECCT uses low-intensity, medium-frequency electrostatic wave energy to target cancer cells. The research focuses on JNK2α2, a protein that plays a role in tumor growth, and looks at how ECCT influences its levels and the number of GBM cells in a laboratory setting. The results show that ECCT can significantly decrease both the amount of JNK2α2 and the number of GBM cells, suggesting it could be a promising complementary treatment option.

Key Findings:

1. Significant Reduction in JNK2α2 Expression: ECCT exposure significantly decreased JNK2α2 expression in U-87MG GBM cells. The reduction was particularly notable at higher intensities (30 and 50 PPV) and longer exposure durations (48 and 72 hours), suggesting that ECCT effectively disrupts the MAPK signaling pathway, which is crucial for cell proliferation and survival.
2. Decrease in Cell Viability and Proliferation: Prolonged ECCT exposure led to a significant reduction in GBM cell counts. The most substantial reduction in cell proliferation was observed at 72 hours, indicating that longer durations of ECCT enhance its anti-proliferative effects.
3. Mechanism of Action: ECCT disrupts the JNK2α2 signaling pathway, which is part of the MAPK pathway involved in cell proliferation and survival. This disruption leads to decreased proliferation and increased apoptosis of GBM cells. Additionally, ECCT affects receptor tyrosine kinase (RTK) interactions on the cell membrane, disrupting downstream signaling pathways like Ras/Raf/MEK/p42/44MAPK, which are essential for cell growth and survival. This disruption inhibits tumor cell proliferation and promotes cell death.
4. Therapeutic Implications: ECCT offers a non-invasive method to target GBM cells, potentially reducing the need for aggressive surgical interventions. The significant reduction in cell proliferation with ECCT highlights its potential as a complementary therapy to existing treatments.
5. Safety and Efficacy: The study demonstrates the safety of ECCT, with no adverse effects on normal cell function observed. The efficacy of ECCT in reducing GBM cell proliferation suggests promising therapeutic outcomes, particularly when used in conjunction with other treatment modalities.
6. Clinical Implications: ECCT offers a promising non-invasive alternative to traditional GBM treatments, which often involve invasive procedures with significant side effects. ECCT could be effectively combined with other treatments to enhance therapeutic outcomes. For example, combining ECCT with chemotherapeutic agents could improve overall efficacy by targeting multiple pathways simultaneously. Ensuring the safety of ECCT is crucial for its clinical application, and this study highlights its safety profile, minimizing concerns about adverse effects.